
In addition, Polyplus has named Dr. Andreas Rummelt and Jean-Paul Mangeolle to its board of directors. Dr. Andreas Rummelt is currently the CEO and partner of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry. Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis and served as a member of the executive committee there. He also held various positions of increasing responsibility in development for Sandoz Pharma Ltd including CEO, Head of Worldwide Technical Research and Development, and Head of Technical Operations of the Novartis Pharmaceuticals Division. In addition to Polyplus, Dr. Rummelt is a member of the board of directors of Alexion Pharmaceuticals, Xellia Pharmaceuticals, and Alvogen, in addition to several international advisory boards.
Jean-Paul Mangeolle has more than 35 years of experience as a global biotechnology executive. He served as President of the SCIEX Group, a unit of Danaher. Prior to SCIEX Group, he was an Executive Vice President with Merck KGaA responsible for the process solutions division and previously held executive positions with Millipore Corporation. In addition to Polyplus, Mr. Mangeolle currently serves on the boards of directors of Charles River Labs, Gelest, and TeraPore Technologies and is a co-founder of Petri Bio, an early stage venture capital firm.
COMMENTS ARE OFF THIS POST